Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
OmniAb, Inc. licenses advanced antibody discovery technologies utilizing genetically engineered transgenic animals and AI-driven screening platforms. Its core offerings include diverse fully human antibody repertoires, high-throughput B cell screening, and bispecific antibody platforms. Serving pharmaceutical, biotech, and academic clients worldwide, OmniAb accelerates therapeutic development across multiple modalities, including antibodies, bispecifics, and ion channel targets, leveraging proprietary animal models and computational tools for efficient, high-quality drug candidate identification.
This description was generated via AI from an annual report. Updated about 1 year ago.